title: Permanent iodine-125 interstitial planar seed brachytherapy for close or positive margins for thoracic malignancies.
abstract: OBJECTIVE
  To assess toxicity and outcome following permanent iodine-125 seed implant as an adjunct to surgical resection in cases of advanced thoracic malignancy.
  
  
  METHODS
  An institutional review board-approved retrospective review was performed. Fifty-nine patients were identified as having undergone thoracic brachytherapy seed implantation between September 1999 and December 2006. Data for patient demographics, tumor details, and morbidity and mortality were recorded.
  
  
  RESULTS
  Fifty-nine patients received 64 implants. At a median follow-up of 17 months, 1-year and 2-year Kaplan-Meier rates of estimated overall survival were 94.1% and 82.0%, respectively. The 1-year and 2-year local control rates were 80.1% and 67.4%, respectively. The median time to develop local recurrence was 11 months. Grades 3 and 4 toxicity rates were 12% at 1 year.
  
  
  CONCLUSIONS
  This review shows relatively low toxicity for interstitial planar seed implantation after thoracic surgical resection. The high local control results suggest that an incomplete oncologic surgery plus a brachytherapy implant for treating advanced thoracic malignancy merit further investigation.
authors.affiliation: Department of Radiation Oncology, Montefiore Medical Center and Albert Einstein College of Medicine in 1625 Poplar St., Bronx, New York, 10461, USA. smutyala@montefiore.org
authors.forename: Subhakar
authors.initials: S
authors.lastname: Mutyala
authors.forename: Alexandra
authors.initials: A
authors.lastname: Stewart
authors.forename: Atif J
authors.initials: AJ
authors.lastname: Khan
authors.forename: Robert A
authors.initials: RA
authors.lastname: Cormack
authors.forename: Desmond
authors.initials: D
authors.lastname: O'Farrell
authors.forename: David
authors.initials: D
authors.lastname: Sugarbaker
authors.forename: Phillip M
authors.initials: PM
authors.lastname: Devlin
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001918:Brachytherapy / Q000009:adverse effects / Q000379:methods*; D002276:Carcinoid Tumor / Q000532:radiotherapy / Q000601:surgery; D002289:Carcinoma, Non-Small-Cell Lung / Q000532:radiotherapy / Q000601:surgery; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use*; D007890:Leiomyosarcoma / Q000532:radiotherapy / Q000601:surgery; D008175:Lung Neoplasms / Q000532:radiotherapy / Q000601:surgery; D008297:Male; D008482:Mediastinum / Q000601:surgery; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D018365:Neoplasm, Residual; D011879:Radiotherapy Dosage; D018714:Radiotherapy, Adjuvant / Q000379:methods; D012189:Retrospective Studies; D012509:Sarcoma / Q000532:radiotherapy / Q000601:surgery; D013899:Thoracic Neoplasms / Q000532:radiotherapy* / Q000601:surgery; D013997:Time Factors; D055815:Young Adult
chemical_list: D007457:Iodine Radioisotopes